Prolotherapy for Musculoskeletal Disorders
Prolotherapy describes a procedure intended for healing and strengthening ligaments and tendons by injecting an agent that induces inflammation and stimulates endogenous repair mechanisms. Prolotherapy may also be referred to as proliferant injection, prolo, joint sclerotherapy, regenerative injection therapy, growth factor stimulation injection, or nonsurgical tendon, ligament, and joint reconstruction. The goal of prolotherapy is to promote tissue repair or growth by prompting release of growth factors, such as cytokines, or by increasing the effectiveness of existing circulating growth factors. The mechanism of action is not well-understood, but may involve local irritation and/or cell lysis. Agents used with prolotherapy include zinc sulfate, psyllium seed oil, combinations of dextrose, glycerine, and phenol, or dextrose alone. Prolotherapy may involve a single injection or a series of injections, often diluted with a local anesthetic.
Prolotherapy for the treatment of musculoskeletal disorders is considered investigational.
Any specific products referenced in this policy are just examples and are intended for illustrative purposes only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available. These examples are contained in the parenthetical e.g. statement.
We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.
Prolotherapy has been investigated as a treatment option of various types of pain. Although there is extensive literature regarding prolotherapy, clinical efficacy has not been proven.
American Association of Orthopaedic Medicine. (2013). Prolotherapy for back pain. Retrieved February 25, 2014 from www.aaomed.org/prolotherapy-back-pain.
BlueCross BlueShield Association. Evidence Positioning System. (11:2018). Prolotherapy (2.01.26). Retrieved March 18, 2019 from https://www.evidencepositioningsystem.com/. (23 articles and/or guidelines reviewed)
Centers for Medicare & Medicaid Services. CMS.gov. NCD for prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents (150.7). Retrieved July 13, 2016 from https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?ncdid=15&ver=1.
Hassan, F., Murrell, W.D., Refalo, A., & Maffulli, N. (2018). Alternatives to biologics in management of knee osteoarthritis: a systematic review. Sports Medicine and Arthroscopic Review, 26 (2), 79-85. Abstract retrieved May 22, 2018 from PubMed database.
Hassan, F., Trebinjac, S., Murrell, W., & Maffulli, N. (2017). The effectiveness of prolotherapy in treating knee osteoarthritis in adults: a systematic review. British Medical Bulletin, 2017. Doi:10.1093/bmb/ldx006. 4, 1-18. [Epub ahead of print]. Abstract retrieved May 24, 2017 from PubMed database.
Hauser, R., Lackner, J., Steilen-Matias, D., & Harris, D. (2016). A systematic review of dextrose prolotherapy for chronic musculoskeletal pain. Clinical Medicine insights: Arthritis and Musculoskeletal Disorders, 139-159. (Level 2 evidence)
Hung, C., Hsiao, M., Chang, K., Han, D., & Wang, T. (2016). Comparative effectiveness of dextrose prolotherapy versus control injections and exercise in the management of osteoarthritis pain: a systematic review and meta-analysis. Journal of Pain Research, 9, 847-858. (Level 2 evidence)
Krstičević, M., Jerić, M., Došenović, S., Jeličić, K., & Puljak, L. (2017). Proliferative injection therapy for osteoarthritis: a systematic review. International Orthopaedics, 41 (4), 671-679. Abstract retrieved May 24, 2017 from PubMed database.
Lin, M.T., Chiang, C.F., Wu, C.H., Huang, Y.T., Tu Y.K., & Wang, T.G. (2019). Comparative effectiveness of injection therapies in rotator cuff tendinopathy: A systematic review, pairwise and network meta-analysis of randomized controlled trials. Archives of Physical Medicine and Rehabilitation, 100 (2), 336-349. Abstract retrieved March 18, 2019 from Pubmed database.
Morath, O., Kubosch, E., Taeymans, J., Zwingmann, J., Konstantinidis, L., Südkamp, N., & Hirschmüller, A. (2017). The effect of sclerotherapy and prolotherapy on chronic painful Achilles tendinopathy – a systematic review including meta-analysis. Scandinavian Journal of Medical & Science in Sports, Doi.10.1111/sms.12898. [Epub ahead of print]. Abstract retrieved May 24, 2017 from PubMed database.
Rabago, D., Mundt, M., Zgierska, A., & Grettie, J. (2015). Hypertonic dextrose injection (prolotherapy) for knee osteoarthritis: long term outcomes. Complementary Therapies in Medicine, 23 (3), 388-395. Abstract retrieved May 24, 2017 from PubMed database.
Rabago, D., Patterson, J., Mundt, M., Zgierska, A., Fortney, L., Grettie, J., et al. (2014). Dextrose and Morrhuate Sodium Injections (Prolotherapy) for Knee Osteoarthritis: A Prospective Open-Label Trial. The Journal of Alternative and Complementary Medicine, 20 (5), 383-391. (Level 3 evidence)
Sanderson, L., & Bryant, A. (2015). Effectiveness and safety of prolotherapy injections for management of lower limb tendinopathy and fasciopathy: a systematic review. Journal of Foot and Ankle Research, 8, 57. (Level 2 evidence)
Sit, R., Chung, V., Reeves, K., Rabago, D., Chan, K., Chan, D., et al. (2016). Hypertonic dextrose injections (prolotherapy) in the treatment of symptomatic knee osteoarthritis: a systematic review and meta-analysis. Scientific Reports, 6:25247. DOI:10.1038/srep25247. (Level 2 evidence)
ORIGINAL EFFECTIVE DATE: 6/1/2000
MOST RECENT REVIEW DATE: 5/9/2019
Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.
This document has been classified as public information.